BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 18424887)

  • 21. Capecitabine monotherapy is efficient and safe in all line settings in patients with metastatic and advanced breast cancer.
    Amari M; Ishida T; Takeda M; Ohuchi N
    Jpn J Clin Oncol; 2010 Mar; 40(3):188-93. PubMed ID: 19887522
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mitoxantrone plus vinorelbine in pretreated patients with metastatic breast cancer.
    Onyenadum A; Gogas H; Markopoulos C; Bafaloukos D; Aravantinos G; Mantzourani M; Koutras A; Tzorakoelefterakis E; Xiros N; Makatsoris T; Fountzilas G; Kalofonos HP
    J Chemother; 2007 Oct; 19(5):582-9. PubMed ID: 18073159
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dose-finding study of weekly docetaxel, epirubicin and capecitabine, as first-line treatment in advanced breast cancer.
    Waters SH; Gillibrand A; Berry H; Kumar S; Velikova G; Dodwell DJ; Perren TJ
    Cancer Chemother Pharmacol; 2009 Jul; 64(2):407-12. PubMed ID: 19455333
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Second-line combination chemotherapy with vinorelbine and capecitabine in patients with advanced breast cancer previously treated with anthracyclines and/or taxanes.
    Mao W; Guan X; Tucker S; Li F; He Z; Wang J; Guo J; Wu S
    Chemotherapy; 2011; 57(1):71-6. PubMed ID: 21293121
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of an all-oral capecitabine and vinorelbine combination regimen on functional status of elderly patients with advanced solid tumours: A multicentre pilot study of the French geriatric oncology group (GERICO).
    Rousseau F; Retornaz F; Joly F; Esterni B; Abadie-Lacourtoisie S; Fargeot P; Luporsi E; Servent V; Laguerre B; Brain E; Geneve J;
    Crit Rev Oncol Hematol; 2010 Oct; 76(1):71-8. PubMed ID: 20356760
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A phase II study of trastuzumab and capecitabine for patients with HER2-overexpressing metastatic breast cancer: Japan Breast Cancer Research Network (JBCRN) 00 Trial.
    Yamamoto D; Iwase S; Kitamura K; Odagiri H; Yamamoto C; Nagumo Y
    Cancer Chemother Pharmacol; 2008 Mar; 61(3):509-14. PubMed ID: 17516068
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and tolerability of capecitabine with weekly paclitaxel for patients with metastatic breast cancer: a phase II report of the SAKK.
    Gick U; Rochlitz C; Mingrone W; Pestalozzi B; Rauch D; Ballabeni P; Lanz D; Hess V; Aebi S
    Oncology; 2006; 71(1-2):54-60. PubMed ID: 17344671
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety profile and activity of lower capecitabine dose in patients with metastatic breast cancer.
    Rossi D; Alessandroni P; Catalano V; Giordani P; Fedeli SL; Fedeli A; Baldelli AM; Casadei V; Ceccolini M; Catalano G
    Clin Breast Cancer; 2007 Dec; 7(11):857-60. PubMed ID: 18269775
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Final results of an international retrospective observational study in patients with advanced breast cancer treated with oral vinorelbine-based chemotherapy.
    Palomo AG; Glogowska I; Sommer H; Malamos N; Kilar E; Vega JM; Torrecillas L; Delozier T; Ettl J; Finek J
    Anticancer Res; 2012 Oct; 32(10):4539-45. PubMed ID: 23060583
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A phase I-phase II study of vinorelbine with cisplatin, 5-fluorouracil, and leucovorin for advanced non-small cell lung cancer.
    Masters GA; Drinkard LC; Hoffman PC; Lane N; Watson S; Samuels BL; Bitran JD; Golomb HM; Vokes EE
    Cancer J Sci Am; 1995; 1(4):288-94. PubMed ID: 9166490
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Vinorelbine plus 3-weekly trastuzumab in metastatic breast cancer: a single-centre phase 2 trial.
    De Maio E; Pacilio C; Gravina A; Morabito A; Di Rella F; Labonia V; Landi G; Nuzzo F; Rossi E; Silvestro P; Botti G; Di Bonito M; Curcio MP; Formichelli F; La Vecchia F; Staiano M; Maurea N; D'Aiuto G; D'Aiuto M; Thomas R; Signoriello G; Perrone F; de Matteis A
    BMC Cancer; 2007 Mar; 7():50. PubMed ID: 17374151
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A phase I study of capecitabine and a modulatory dose of irinotecan in metastatic breast cancer.
    O'connor T; Rustum Y; Levine E; Creaven P
    Cancer Chemother Pharmacol; 2008 Jan; 61(1):125-31. PubMed ID: 17426973
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A multicentre dose-escalating study of cabazitaxel (XRP6258) in combination with capecitabine in patients with metastatic breast cancer progressing after anthracycline and taxane treatment: a phase I/II study.
    Villanueva C; Awada A; Campone M; Machiels JP; Besse T; Magherini E; Dubin F; Semiond D; Pivot X
    Eur J Cancer; 2011 May; 47(7):1037-45. PubMed ID: 21339064
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Capecitabine and oxaliplatin (XELOX) as first-line treatment for patients with metastatic colorectal cancer.
    Karacetin D; Yalcin B; Okten B; Ozturk S; Maral O; Incekara O
    J BUON; 2009; 14(4):605-8. PubMed ID: 20148449
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Single-agent capecitabine maintenance therapy after response to capecitabine-based combination chemotherapy in patients with metastatic breast cancer.
    Huang H; Jiang Z; Wang T; Zhang S; Bian L; Cao Y; Wu S; Song S
    Anticancer Drugs; 2012 Aug; 23(7):718-23. PubMed ID: 22739713
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intravenous versus oral vinorelbine plus capecitabine as second-line treatment in advanced breast cancer patients. A retrospective comparison of two consecutive phase II studies.
    Lorusso V; Cinieri S; Giampaglia M; Ciccarese M; Tinelli A; Chiuri V; Manca C; Silvestris N; Gasparini G; Colucci G
    Breast; 2010 Jun; 19(3):214-8. PubMed ID: 20167491
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sorafenib in combination with capecitabine: an oral regimen for patients with HER2-negative locally advanced or metastatic breast cancer.
    Baselga J; Segalla JG; Roché H; Del Giglio A; Pinczowski H; Ciruelos EM; Filho SC; Gómez P; Van Eyll B; Bermejo B; Llombart A; Garicochea B; Durán MÁ; Hoff PM; Espié M; de Moraes AA; Ribeiro RA; Mathias C; Gil Gil M; Ojeda B; Morales J; Kwon Ro S; Li S; Costa F
    J Clin Oncol; 2012 May; 30(13):1484-91. PubMed ID: 22412143
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase I study of oral vinorelbine and capecitabine in patients with metastatic breast cancer.
    Anton A; Lluch A; Casado A; Provencio M; Muñoz M; Lao J; Bermejo B; Paules AB; Gayo J; Martin M
    Anticancer Res; 2010 Jun; 30(6):2255-61. PubMed ID: 20651377
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The combination of thalidomide and capecitabine in metastatic renal cell carcinoma -- is not the answer.
    Harshman LC; Li M; Srinivas S
    Am J Clin Oncol; 2008 Oct; 31(5):417-23. PubMed ID: 18838876
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Individualized chemotherapy based on organ selectivity: a retrospective study of vinorelbine and capecitabine for patients with metastatic breast cancer.
    Liu XH; Man YN; Cao R; Liu C; Wu XZ
    Curr Med Res Opin; 2014 Jun; 30(6):1017-24. PubMed ID: 24528110
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.